Archive: February 10 2021
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
FDA approves cell-based gene therapy to treat adults with relapsed or refractory...
Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
Liso-Cel Responses Not Impacted By Prior Anti-CD19 Therapy in Relapsed/Refractor...
Prior exposure to anti-CD19 therapy did not impact response to the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
Management of DLBCL With CAR T-Cell Therapy: Case-based discussion
During a Targeted Oncology Case-Based Peer Perspectives virtual event, Jason Westin, MD, MS, evaluated the management of a 63-year-old patient with diffuse large B-cell lymphoma.
Cancer Immunotherapy: 2021 Research and Look Ahead - Webinar for patrients and c...
CRI Scientific Advisory Council Associate Director Dr. Kunle Odunsi discusses the future of cancer immunotherapy and what may lie ahead for the field.